Appreciate the views.What would you consider as the key...

First 7 Last

Share
Profile

Follow
HoopsOz

12 Posts.

17/05/24

11:17

Post #: 73874825
Share

Originally posted by TheAnalyst007: ↑

The US market is the focus for the company at the moment, that's where the growth is happening and is where 99% of marketing resources are being allocated. It also makes up the vast majority of their revenue. Last half that was up 65%, first couple months of this year were also up a similarly high rate. That was on a reasonably large base and before the significant expansion in their sales team (from only 6 reps previously) and marketing effort though, and based on an explosion in social media activity around iTrack Advance and significant increase in their presence at the major conferences, it seems fairly likely we will see this growth rate accelerate (particularly in the second half of calendar year 2025, but also the current half as well). Given they're not yet focused on the global market outside the US, global growth has been lagging (they have existing revenue from the previous device) which makes the over all figure look a little less exciting. However I suspect when they focus more resources outside the US, and they get more approvals in these markets, the growth rate will be as strong as it has been in the USA (particularly in China).

They have a large number of patents protecting the key features of their device, thanks to originally pioneering the canaloplasty space with their original iTrack device. Sight Sciences tried to create a similar device, but it's not even close. It can only do half of an eye at a time (not the full eye all at once), has no navigational system and no pressurised visco delivery (which means they get about 10% of the strength of iTrack Advance - requiring the use of an additional tearing procedure).

Expand

Appreciate the views.

What would you consider as the key risks?

Competition?
If the US requires significant marketing to get traction, do they have enough funding with the last CR to keep momentum up?

EYE Price at posting: 24.0¢ Sentiment: Buy Disclosure: Held
Upvote

0 Great analysis

Reply

Top Stories

SPR

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

MSB

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

PL3

Patagonia looks to raise $2.15M for South American exploration and development

SRL

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

OCC

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

There are more pages in this discussion • 8 more messages in this thread...

First 7 Last

Add EYE (ASX) to my watchlist

(20min delay)
Last 26.5¢		Change -0.025(8.62%)		Mkt cap ! $60.63M

Open	High	Low	Value	Volume
29.0¢	29.5¢	26.5¢	$332.8K	1.182M

Buyers (Bids)

No.	Vol.	Price($)
6	121450	26.5¢

Sellers (Offers)

Price($)	Vol.	No.
27.5¢	154073	4

View Market Depth

No.	Vol.	Price($)
6	121450	0.265
7	169422	0.260
2	120000	0.255
4	57500	0.250
2	70816	0.245

Price($)	Vol.	No.
0.275	154073	4
0.280	120284	4
0.285	70645	2
0.290	175543	4
0.295	41369	5

Last trade - 16.10pm 09/07/2024 (20 minute delay)

EYE (ASX) Chart

Appreciate the views.What would you consider as the key...

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Appreciate the views.What would you consider as the key...

Top Stories

Spartan sniffs 126g/t gold ahead of resource upgrades at WA's Dalgaranga

Mesoblast resubmits US FDA application for approval of Ryoncil in children with graft vs host disease; shares dip -4%

Patagonia looks to raise $2.15M for South American exploration and development

Scandium a priority metal for Sunrise as it plans feasibility update at Syerston

Orthocell shares jump on record revenues from sales of collagen bone repair devices globally

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News